Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record.

A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Eppler, Stephen M., Combs, Daniel L., Henry, Timothy D., Lopez, John J., Ellis, Stephen G., Yi, Joo‐Hee, Annex, Brian H., McCluskey, Edward R., Zioncheck, Thomas F.·2002·Clinical Pharmacology & Therapeutics

Abstract

Background: The Vascular Endothelial Growth Factor (VEGF) in Ischemiafor Vascular Angiogenesis (VIVA) trial was a double‐blind, placebo‐controlled, phase II clinical trial designed to evaluate the safety, efficacy, and pharmacokinetics of combinedintracoronary and intravenous infusions of recombinant human vascular endothelial growth factor (rhVEGF 165) for therapeutic angiogenesis. This study describes the use of a mechanism‐based model to characterize the nonlinear kinetics observed after intravenous administration of rhVEGF 165. The model predicts that rhVEGF 165 distribution occurs through both saturable binding to high‐affinity receptors and reversible interactions with low‐affinity binding sites. Methods: In this trial, rhVEGF 165 was administered to patients with coronary artery disease at a dose rate of 17 or 50 ng/kg/min by means of intracoronary infusion for 20 minutes, followed by three 4‐hour intravenous infusions on days 3, 6, and 9. Pharmacokinetic samples and blood pressure measurements were collected at baseline, during infusion, and for 6 hours after infusion. Results: The plasma clearance, steady‐state volume of distribution, and terminal half‐life after a 4‐hour intravenous infusion of rhVEGF 165 at the high dose were 19.1 ± 5.7 mL/min/kg, 960 ± 260 mL/kg, and 33.7 ± 13 minutes, respectively. The duration of hypotension that occurred after rhVEGF 165 administration appeared to be related to the model‐predicted VEGF 165 concentration associated with the high‐affinity receptor compartment. Conclusions: This mechanism‐based model accurately predicted VEGF concentrations and allowed for the simulation of various rhVEGF 165 dose regimens that may aid in optimization of drug delivery for future clinical trials. Clinical Pharmacology & Therapeutics (2002) 72, 20–32; doi: 10.1067/mcp.2002.126179

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1067/mcp.2002.126179

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 266

Metadata

Authors
Eppler, S. M., Combs, D. L., Henry, T. D., Lopez, J. J., Ellis, S. G., Yi, J., Annex, B. H., McCluskey, E. R., & Zioncheck, T. F.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-07
Volume
72
Issue
1
Pages
20-32
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W1994322982
Cited by
266
References
0
FWCI
2.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. https://app.cochat.ai/papers/10.1067/mcp.2002.126179
The paper
Eppler, S. M., Combs, D. L., Henry, T. D., Lopez, J. J., Ellis, S. G., Yi, J., Annex, B. H., McCluskey, E. R., & Zioncheck, T. F. (2002). A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.126179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.